Biomarin

15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Yahoo/Zacks.com
Mon, 12/10/18 - 09:50 am
M&A
Biomarin
Vertex Pharmaceuticals
Incyte
Alnylam
Alexion
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
Sat, 10/20/18 - 11:16 pm
earnings
biotech
Biogen
Alexion Pharmaceuticals
Bristol-Myers Squibb
Celgene
Gilead Sciences
Merck
Biomarin
Galapagos
Seattle Genetics
Dr Reddy's
3 Biotech Stocks With Virtual Monopolies
Motley Fool
Wed, 10/3/18 - 11:53 am
Alexion Pharmaceuticals
Biomarin
Vertex Pharmaceuticals
Express Scripts staking out million-dollar gene therapies
Reuters
Wed, 08/15/18 - 10:32 pm
Express Scripts
PBMs
gene therapies
drug pricing
Biomarin
Bluebird Bio
Spark Therapeutics
BioMarin Pharmaceutical Sets Its Sights on $2 Billion
Motley Fool
Tue, 08/7/18 - 11:43 pm
Biomarin
earnings
BioMarin Begins Pediatric Study on Achondroplasia Candidate
Yahoo/Zacks.com
Sat, 06/16/18 - 01:30 pm
Biomarin
clinical trials
vosoritide
achrondoplasia
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
Tue, 06/5/18 - 10:37 pm
valrox
Biomarin
hepatitis A
risankizumab
AbbVie
Boehringer Ingelheim
psoriasis
BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)
CP Wire
Fri, 05/25/18 - 09:15 am
Biomarin
Palynziq
PKU
FDA
BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)
Fri, 05/25/18 - 08:45 am
Biomarin
Palynziq
PKU
A Big Decision Is Fast-Approaching for This Rare-Disease Drugmaker
Motley Fool
Wed, 05/23/18 - 03:06 pm
Biomarin
pegvaliase
PKU
FDA
Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study
Endpoints
Tue, 05/22/18 - 09:58 am
Biomarin
hemophilia A
valrox
BioMarin Cruises While It Waits on Seventh Approval
Motley Fool
Fri, 04/27/18 - 08:15 pm
Biomarin
pegvaliase
FDA
PKU
earnings
8 Takeout targets to watch in 2018
BioPharma Dive
Sat, 12/16/17 - 08:41 am
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
[video]ASH 2017 Recap: These Were the Big Winners and Losers
Motley Fool
Sat, 12/16/17 - 08:39 am
ASH2017
Bluebird Bio
Juno Therapeutics
Spark Therapeutics
Biomarin
JNJ
Celgene
ASH 2017: What you missed
BioPharma Dive
Wed, 12/13/17 - 06:35 pm
ASH17
Biomarin
Spark Therapeutics
Gilead Sciences
Novartis
Juno Therapeutics
AbbVie
Roche
JNJ
5 Biotech Buyout Candidates for 2018
Yahoo/Motley Fool
Wed, 12/13/17 - 09:36 am
biotech
M&A
Biogen
Biomarin
Bluebird Bio
Geron
SAGE Therapeutics
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
BioPharma Dive
Tue, 12/12/17 - 10:50 pm
ASH17
Spark Therapeutics
gene therapy
Biomarin
hemophilia A
SPK-8011
ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia
BioPharma Dive
Sat, 12/9/17 - 02:31 pm
ASH17
Biomarin
gene therapy
hemophilia A
valoctocogene
How much is an FDA shortcut worth to drug developers hustling to an OK? Holding steady at $125M, cash
Endpoints
Mon, 11/27/17 - 11:42 pm
FDA
priority review vouchers
Biomarin

Pages